C12orf66

Across TCGA pan-cancer cohorts, C12orf66 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated C12orf66 data layer compared with 27 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher C12orf66 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated C12orf66 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

CCRCC, GBM, and LSCC are the cancer types where C12orf66 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	IV	0.135	0.784	.038	10	view →
GBM	DFS	Tertile	All	0.527	0.833	.030	7	view →
LSCC	OS	Median	All	1.000	0.938	.014	7	view →
LUAD	DFS	Quartile	All	0.798	0.987	.024	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

C12orf66–CCRCC (DFS)

Open the CCRCC breakdown →